Department of General, Visceral and Transplant Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), University Hospital Heidelberg, Heidelberg, Germany.
BJS Open. 2022 Jan 6;6(1). doi: 10.1093/bjsopen/zrab130.
Patients with hepatocellular carcinoma (HCC) are selected for transplantation if they have a low tumour burden and low risk of recurrence. The morphometric Milan criteria have been the cornerstone for patient selection, but dynamic morphological and biological tumour characteristics surfaced as an encouraging tool to refine the selection of patients with HCC and to support the expansion of the Milan criteria. The outcomes of the most prevalent models that select patients with HCC for liver transplantation were analysed in this study, which aimed to identify the selection model that offered the best recurrence-free and overall survival after transplantation.
Studies that compared Milan, University of California San Francisco (UCSF), up-to-seven (UPTS), alpha-fetoprotein (AFP), and MetroTicket 2.0 (MT2) models were included. One-year, 3-year, and 5-year recurrence-free and overall survival rates of patients selected for transplantation using different models were analysed.
A total of 60 850 adult patients with HCC selected for liver transplantation using Milan, UCSF, UPTS, AFP, or MT2 criteria were included. Patients selected for transplantation using the MT2 model had the highest 1-, 3-, and 5-year recurrence-free survival. In addition, patients selected for transplantation using MT2 criteria had the best 1- and 3-year overall survival, whereas patients selected for transplantation using the Milan criteria had the best 5-year overall survival rates.
The MT2 model offered the best post-transplant outcomes in patients with HCC, highlighting the importance of considering tumour morphology and biology when selecting patients with HCC for liver transplantation.
如果肝癌 (HCC) 患者的肿瘤负荷低且复发风险低,则选择进行移植。形态计量米兰标准一直是患者选择的基石,但动态形态和生物学肿瘤特征已成为一种有前途的工具,可以完善 HCC 患者的选择,并支持米兰标准的扩展。本研究分析了最常见的选择 HCC 患者进行肝移植的模型的结果,旨在确定哪种选择模型在移植后提供最佳的无复发生存和总体生存。
本研究纳入了比较米兰、加利福尼亚大学旧金山分校 (UCSF)、至七 (UPTS)、甲胎蛋白 (AFP) 和 MetroTicket 2.0 (MT2) 模型的研究。分析了使用不同模型选择进行移植的患者的 1 年、3 年和 5 年无复发生存率和总生存率。
共纳入了 60850 名使用米兰、UCSF、UPTS、AFP 或 MT2 标准选择进行肝移植的成年 HCC 患者。使用 MT2 模型选择进行移植的患者的 1 年、3 年和 5 年无复发生存率最高。此外,使用 MT2 标准选择进行移植的患者的 1 年和 3 年总生存率最佳,而使用米兰标准选择进行移植的患者的 5 年总生存率最佳。
MT2 模型为 HCC 患者提供了最佳的移植后结局,强调在选择 HCC 患者进行肝移植时考虑肿瘤形态和生物学的重要性。